NAV

Rufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Rufloxacin is a fluoroquinolone antibiotic indicated in the treatment of susceptible respiratory infections and uncomplicated cystitis.

Generic Name
Rufloxacin
DrugBank Accession Number
DB13772
Background

Rufloxacin is a quinolone antibiotic. 1

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 363.407
Monoisotopic: 363.105290352
Chemical Formula
C17H18FN3O3S
Synonyms
  • Rufloxacin
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute uncomplicated bacterial cystitis••••••••••••••••••
Treatment ofChronic bronchitis••••••••••••••••••
Treatment ofChronic obstructive pulmonary disease (copd)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Rufloxacin.
AceclofenacAceclofenac may increase the neuroexcitatory activities of Rufloxacin.
AcemetacinAcemetacin may increase the neuroexcitatory activities of Rufloxacin.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Rufloxacin.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Rufloxacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Rufloxacin hydrochloride1643374N6L106017-08-7LPQOADBMXVRBNX-UHFFFAOYSA-N

Categories

ATC Codes
J01MA10 — Rufloxacin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzothiazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines
show 16 more
Substituents
1,4-diazinane / Alkylarylthioether / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Aryl thioether
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, quinolone antibiotic, fluoroquinolone antibiotic (CHEBI:8909)
Affected organisms
Not Available

Chemical Identifiers

UNII
Y521XM2900
CAS number
101363-10-4
InChI Key
NJCJBUHJQLFDSW-UHFFFAOYSA-N
InChI
InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)
IUPAC Name
7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3CCSC1=C23)C(O)=O

References

General References
  1. Rafalsky V, Andreeva I, Rjabkova E: Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003597. doi: 10.1002/14651858.CD003597.pub2. [Article]
  2. AIFA Product Information: MONOS (Rufloxacin hydrochloride) oral tablet [Link]
Human Metabolome Database
HMDB0042009
KEGG Drug
D02474
KEGG Compound
C11240
ChemSpider
52489
ChEBI
8909
ChEMBL
CHEMBL295619
ZINC
ZINC000000538328
Wikipedia
Rufloxacin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral150 MG
TabletOral200 MG
Tablet, coatedOral150 MG
Tablet, coatedOral200 MG
Tablet, coatedOral
Tablet, film coated
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.96 mg/mLALOGPS
logP0.13ALOGPS
logP0.3Chemaxon
logS-2.6ALOGPS
pKa (Strongest Acidic)5.33Chemaxon
pKa (Strongest Basic)6.57Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area64.09 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity97.02 m3·mol-1Chemaxon
Polarizability36.42 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-052b-2029000000-57eac386d480df63c717
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03k9-0169000000-0ec29246738d7398bc4e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-0009000000-5f480c634391f933a9c2
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03dj-0069000000-e14021e4ee31255875ba
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0009000000-22728aadae9be28a9b40
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0029000000-4ffd78caf04ebb47af89
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0009000000-6141e98613610e1e9a14
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kf-0169000000-aa2b7807c63d0461d9b1
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-191.5912371
predicted
DarkChem Lite v0.1.0
[M-H]-180.43742
predicted
DeepCCS 1.0 (2019)
[M+H]+192.5265371
predicted
DarkChem Lite v0.1.0
[M+H]+182.79543
predicted
DeepCCS 1.0 (2019)
[M+Na]+191.7211371
predicted
DarkChem Lite v0.1.0
[M+Na]+189.5111
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 1A2
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
Curator comments
This drug is a quinolone derivative, and these agents are known to inhibit CYP1A2.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Shahzadi A, Javed I, Aslam B, Muhammad F, Asi MR, Ashraf MY, Zia-ur-Rahman: Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011 Jan;24(1):63-8. [Article]
  2. Zhang L, Wei MJ, Zhao CY, Qi HM: Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008 Dec;29(12):1507-14. doi: 10.1111/j.1745-7254.2008.00908.x. [Article]
  3. Brosen K: Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12. [Article]
  4. Danie WA, Syrek M, Rylko Z, Wojcikowski J: Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. Pol J Pharmacol. 2001 Jul-Aug;53(4):351-7. [Article]

Drug created at June 23, 2017 20:48 / Updated at May 22, 2021 06:01